Actively Recruiting
Acetazolamide Per os for Decompensation of Heart Failure
Led by Samara State Medical University · Updated on 2024-11-05
400
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually. Acute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.
CONDITIONS
Official Title
Acetazolamide Per os for Decompensation of Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women aged 18 years and older
- Decompensated chronic heart failure NYHA class II-IV requiring intravenous diuretics
- Any left ventricular ejection fraction
- Signed informed consent to participate
- For patients with LVEF ≥ 50%, presence of structural heart changes and/or diastolic dysfunction and/or elevated BNP or NT-proBNP levels according to specified age thresholds
You will not qualify if you...
- Use of acetazolamide within one month before hospitalization
- Expected use of intravenous inotropes, vasopressors, or sodium nitroprusside during the study
- Expected exposure to nephrotoxic agents within the next 3 days
- Allergy to acetazolamide, sulfonamides, or drug components
- Systolic blood pressure below 90 mmHg
- Pregnancy or lactation
- Low potassium (below 3.5 mmol/l) or low sodium (below 135 mmol/l)
- Severe chronic kidney failure (creatinine clearance less than 10 ml/min) or prior renal replacement therapy
- Metabolic acidosis (bicarbonate less than 12 mmol/L)
- Severe anemia (hemoglobin below 70 g/L)
- Acute kidney failure
- Addison's disease
- Decompensated diabetes mellitus
- Emergency conditions such as myocardial infarction, pulmonary embolism, acute myocarditis, pericarditis, or aortic aneurysm
- Liver cirrhosis with encephalopathy or liver failure
- Congenital heart defects
- Active or terminal cancer
- Hypocorticism
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samara state medical university
Samara, Russia, 443099
Actively Recruiting
Research Team
D
Dmitriy Duplyakov, MD
CONTACT
O
Olesya Rubanenko, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here